10x Genomics Lifts Atera Shipment Target to 50
Atera began global commercial shipments in September, and the company now expects to ship about 50 instruments by year-end 2026.
Updated on Nov. 7, 2026 in Biotech

10x Genomics raised its 2026 revenue outlook to $625 million to $635 million, up from a prior range of $610 million to $630 million. The company also lifted its year-end target for Atera instrument shipments to approximately 50, from about 40. Atera is shipping now: global commercial shipments began in September, following its April introduction as an in situ spatial biology platform.
Why it matters
The revision reflects third-quarter performance, stronger-than-anticipated spatial consumables sales, and the higher Atera shipment outlook. The forecast excludes one-time license and royalty income from patent settlements, so the underlying growth is the more telling figure.
Third-quarter revenue reached $150.7 million, up 1% from $149 million a year earlier, a modest pace against which the company has raised its full-year range. The updated outlook implies 4% to 6% growth over 2025 once one-time patent-settlement income is removed, and the Atera target of about 50 instruments is up from roughly 40.
The players
10x Genomics
A life-sciences tools company whose spatial biology and single-cell platforms measure gene activity in tissue and individual cells.
The details
10x Genomics sells instruments and consumable reagents used to measure gene activity in biological samples. Atera is designed for whole-transcriptome analysis, meaning it captures activity across the full set of genes, with single-cell sensitivity, so individual cells can be distinguished. Because it runs in situ, the measurement happens on tissue in place rather than after the tissue is dissociated, which preserves where each cell sits in the sample. Consumables sold for the platform are a recurring revenue stream, which is why the company cites stronger-than-anticipated spatial consumables as a driver of the revision.
Timeline
April 2026: Atera introduced as an in situ spatial biology platform.
September 2026: Global commercial shipments of Atera began.
September 30, 2026: Third-quarter period ended with $150.7 million in revenue.
Year-end 2026: Target of approximately 50 Atera instrument shipments.
The Tech Race
Atera is positioned as an in situ spatial biology platform for whole-transcriptome analysis with single-cell sensitivity. The company's shipment ramp from roughly 40 to about 50 instruments by year-end is the measurable marker of how quickly it is gaining placement in research labs.
Research labs and core facilities that buy spatial biology tools are the groups most directly affected, since Atera began global commercial shipments in September. Pricing and timing for individual buyers are not stated in the source.
The takeaway
Watch whether 10x Genomics reaches its target of approximately 50 Atera shipments by year-end, a figure the company will be measured against in its next quarterly results. Consumables revenue growth is the other signal to track, since it indicates how much installed-base use is building around the platform.
Further reading
For broader context on the tools behind this shift, see Biotech coverage.
Source note: This article includes information reported by TokenPost.





